Basic Search
|
Summaries
|
Advanced SearchViolation Tracker Individual Record
Company: Valeant Pharmaceuticals International, Inc.
Current Parent Company:
Bausch Health
Parent at the Time of the Penalty Announcement:
subscribe to see this data field
Penalty: $37,500,000
Year: 2012
Date: November 7, 2012
Offense Group: competition-related offenses
Primary Offense: price-fixing or anti-competitive practices
Secondary Offense: generic drug pay for delay
Mega-Scandal:
Generic Drug Pay for Delay
Violation Description: Valeant agreed to pay over $37 million to direct purchaser plaintiffs to settle litigation alleging that its subsidiary Biovail conspired to block the introduction of a generic version of its antidepressant Wellbutrin XL.
Level of Government: federal
Action Type: private litigation
Court: Eastern District of Pennsylvania
Civil or Criminal Case: civil
Case ID: 2:08cv2431
Case Name: Meijer, Inc. et al v. Biovail Corporation et al
Private Lawsuit Resolution Type: settlement
HQ Country of Current Parent: Canada
Ownership Structure of Current Parent: publicly traded
Major Industry of Current Parent: pharmaceuticals
Specific Industry of Current Parent: pharmaceuticals
Source of Data:
(click here)
Link to PACER Case Docket (must be logged in):
(click here)
Link to Archived Court Document:
subscribe to see this data field
Source Notes: If an online information source is not working, check the Violation Tracker
Data Sources page for an updated link.
Current parent company note: Parent-subsidiary relationship is current as of the most recent revision listed in the
Update Log.